Arsenal Biosciences, Inc., a clinical stage, programmable cell therapy company engineering advanced CAR T cell therapies for solid tumors, founded by UCSF Researchers Alex Marson, PhD, and Kole Roybal, PhD, today announced that the first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. AB-1015 is ArsenalBio’s first internally discovered T cell medicine to enter clinical development and uses synthetic DNA programming to overcome tumor defenses, increase potency, and target ovarian cancer cells without harming normal tissues.
